Alpine Capital’s Post

A reverse merger for Nasdaq listing of Indian clinical stage specialty pharma co, an acquisition by a separate Indian medical device firm and a future exit window for clutch of VCs (some with long term conviction on this decade plus original bet) #reversemerger #healthcare #pharmaceuticals #venturecapital #nasdaq Navam Capital Iron Pillar Kalaari Capital

New Post: PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders. -On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here’s what it plans to do withe the proceeds. Source link On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here's what it plans to do withe the proceeds. Source link

New Post: PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders. -On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here’s what it plans to do withe the proceeds. Source link On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here's what it plans to do withe the proceeds. Source link

New Post: PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders. -On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here’s what it plans to do withe the proceeds. Source link On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here's what it plans to do withe the proceeds. Source link

New Post: PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders. -On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here’s what it plans to do withe the proceeds. Source link On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here's what it plans to do withe the proceeds. Source link

Exciting times in the #healthcare industry! 🚀 CVC CAPITAL PARTNERS LIMITED is acquiring Mallinckrodt Pharmaceuticals's Therakos business for $925M, marking a significant #investment in advanced extracorporeal photopheresis. 💼 #Therakos, widely used in the US, Europe, and beyond, will see enhanced R&D and geographic #expansion under CVC. Key employees will transition with the business, ensuring seamless support and #innovation.🏥 This strategic move also allows Mallinckrodt Pharmaceuticals to reduce net debt and focus on core priorities.🌍 🔗Read More - https://lnkd.in/dhkNJmn3 🖊️Writes - Dr. Jayati Dubey 🌐Stay Informed with our Latest Stories – https://lnkd.in/gMUPB2Zp   #Healthcare #Pharma #Investment #Therakos #CVC #Innovation #GlobalExpansion #Immunotherapy

Billion-dollar bets on antibody–drug conjugates Multiple deals are being summarized below Last year was an outstanding period for deals focused on antibody–drug conjugates (ADCs), with Pfizer’s $43 billion acquisition of Seagen and AbbVie’s $10.1 billion buyout of ImmunoGen being among the highlights1. The popularity of the ADC platform has persisted in 2024, leading to several acquisitions and licensing deals with potential values in the billion-dollar range (as detailed in the deal snapshots). Demand for ADC assets and technology is supported by recent therapeutic and commercial successes. For example, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) brought in revenues of more than $2.5 billion for these partners in 2023, which was its fourth full year on the market.

This week, MWP Partners became substantial holders of Island Pharmaceuticals, alongside some biotech heavies (with significantly more scientific pedigree than our own) including Daniel Tillett, Jason Carroll, Bill Garner and Chris Ntoumenopoulos. The capital provided will ensure Island can fully fund its Phase 2a/b trial targeting Dengue Fever and fast track the acquisition of Galidesivir, which primarily targets Ebola. What attracted us to this opportunity: - Large (and growing) market opportunity with Dengue infecting an estimate 400m people annually and no current treatment. - Dengue is becoming a ‘rich country’ problem with global warming expanding carrying mosquitos beyond equatorial regions into Southern America, Southern Europe and Northern Australia. - ILA-101 is a small molecule with clinical history. Having previously been developed by J&J for oncology, it has high safety profile and is well tolerated based on 45 human studies. Animal and cell studies, which for antivirals has great translation into humans, further show ILA-101 prevents viral replication and deaths from lethal Dengue. - The US Army, who are a natural stockpiler of an approved drug, is providing no-dilutive funding and cooperating with its R&D library to provide diluted strains of the virus for Island’s Phase 2 trial. - Dengue is the tip of the iceberg, with many other mosquito-borne disease targets including Zika, West Nile and Yellow Fever. - Island could be eligibile to receive Priority Review Voucher(s) following FDA approval for both ILA-101 and Galidesivir, which can be sold to big pharma for >US$100m a piece, providing substantial dilution-free funding. - Galidesivir has a potentially rapid pathway to market under the FDA’s ‘Animal Rule’, requiring only animal trials given the obvious unethical and safety concerns putting Ebola into humans. The market is beginning to recognise Island's potential and is off to a strong start as we await first readout of the Phase 2a results in November. Follow the journey and hope we put a dent in these crippling viruses. https://lnkd.in/g7-9hDDB

Enosium Life Science announces three strategic acquisitions in France and the UK: Inbeeo, Vyoo Agency, and Epione group, aiming to become the European leader in Life Science consulting. 🎯 With its first three acquisitions, Enosium Life Science, supported by Otium, reaffirms its ambition to build a multi-specialist group dedicated to life sciences across the entire value chain of healthcare products, from clinical development to commercialization. ✅ According to Antoine Amer, CEO and Founder of Enosium Life Science: "We aim to be the partner of choice for pharmaceutical, biotech, and medtech companies by offering highly specialized scientific services across Europe and throughout the entire healthcare product value chain." 👇 Find the full press release below 👇  https://lnkd.in/e8q9EykR Antoine Bassel Amer, Founder and CEO of Enosium Life Science Herve Lilliu, President and Founder of Inbeeo Stephane Roze, President and Founder of Vyoo Catherine Auzimour, Pierre-Louis PROST, Groupe Epione, KPL, Alinéa Plus, Sirius François Durvye, General Director at Otium Capital Basile Paul-Petit, Partner at Otium Capital Gabriel MARTIN #HealthInnovation #Healthtech #Biotech #Medtech #Pharmaceuticals #FranceBiotech #LEEM  

AstraZeneca PLC (LSE:AZN) is poised to maintain its full-year financial guidance without adjustments when it announces its first-quarter results later this month (April 25), according to insights from Shore Capital, which expects any significant updates to be unveiled at the drugs giant's capital markets day on May 21. The company's cancer drugs, Imfinzi and Imjudo, are expected to show a robust performance, despite mandatory price cuts in Japan affecting the former. Sticking with oncology, AZ's Tagrisso has seen positive developments with new US Food & Drug Administration approvals and inclusion in national reimbursement lists, addressing concerns about its market competition. Shore also highlighted advances in its rare disease portfolio, including FDA nods for Ultomiris and Voydeya, enhancing its treatment offerings for NMOSD and PNH respectively. On the mergers and acquisitions front, AZ is expected to... More at #Proactive #ProactiveInvestors http://ow.ly/eFC9105pvWy